Capricor Therapeutics Inc. (CAPR) will be presenting results from its phase 3 clinical study of lead cell therapy candidate Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, dubbed HOPE-3, at the Muscular Dystrophy Association Clinical and Scientific Conference on March 11, 2026.
The topline results from the HOPE-3 study, reported last December, were encouraging. The study met the primary endpoint of PUL v2.0 (Performance of Upper Limb) and the key secondary cardiac endpoint of LVEF (Left Ventricular Ejection Fraction), demonstrating statistically significant improvements in both skeletal and cardiac function.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.